Latanoprost NDC 68071-2376

NDC codes

FDA NDC Directory

Product NDC (as listed)68071-2376Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68071-2376Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68071-2376-2	68071237602	1 BOTTLE in 1 CARTON (68071-2376-2) / 2.5 mL in 1 BOTTLEMarketed from Mar 26, 2021

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Latanoprost
Generic name (nonproprietary): latanoprost
Active ingredients: Latanoprost — 50 ug/mL
Dosage form: Solution/ drops
Route: Ophthalmic
Labeler: NuCare Pharmaceuticals,Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 201786
Marketing start: Dec 3, 2019
Listing expires: Dec 31, 2027
Identifiers: Product ID 68071-2376_5aae7a05-5a81-e5e2-e063-6394a90a61eaSPL ID 5aae7a05-5a81-e5e2-e063-6394a90a61eaSPL set ID be74d517-7f73-a74c-e053-2a95a90a3819RxCUI 314072UNII 6Z5B6HVF6OUPC 0368071237627

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Ophthalmic products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468071237602 followed by a unit qualifier and the quantity

Package 68071-2376-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 4, 2026.

Indications (excerpt from the label)

Latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Latanoprost ophthalmic solution is a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 201786

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 201786
Product	Strength	Form · route	Labeler	Product NDC
Latanoprost	Latanoprost 50 ug/mL	Solution/ dropsOphthalmic	Somerset Therapeutics, LLC	70069-421